Enters agreement with Edmonton, Alberta-based Biomira to license existing and future antibodies for cancer indications. The non-equity deal grants Sterling Winthrop an option to the antibodies on a product-by-product basis in exchange for royalties. With the signing of the deal, Sterling Winthrop exercises its option on Biomira's 174 antibody, which is in preclinical development for use against squamous cell carcinomas of the cervix, lung, and head and neck.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth